Cuprina (Cayman) (CUPR) vs CollPlant Biotechnologies (OPHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cuprina (Cayman) is the larger company by market cap ($10.8 million vs $9.6 million), about 1.1 times the size, while CollPlant Biotechnologies is growing revenue faster (+360.4% vs +9.2%). CollPlant Biotechnologies converts more of its revenue into profit, with a net margin of -484.6% versus -9366.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUPR | OPHI |
|---|---|---|
| Share price | $1.41 | $3.13 |
| Market cap | $10.79M | $9.63M |
| 1-day change | -6.00% | -2.49% |
| YTD return | -55.94% | — |
| 1-year return | -75.18% | — |
| EPS (TTM) | $-1.40 | $-9.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $38.79K | $2.37M |
| Revenue growth (YoY) | +9.20% | +360.39% |
| Net income (latest FY) | $-3.63M | $-11.49M |
| Gross margin | -1.29% | 64.78% |
| Operating margin | -9680.12% | -484.31% |
| Net margin | -9366.70% | -484.56% |
| 52-week high | $14.80 | $22.50 |
| 52-week low | $1.38 | $2.64 |
| Distance from 52-week high | -90.47% | -86.09% |
| Average volume | 115.59K | 385.37K |
| Shares outstanding | 5.89M | 3.08M |
| Employees | 10 | — |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CollPlant Biotechnologies is more profitable, keeping -484.6 cents of every revenue dollar as net income versus -9366.7 cents for Cuprina (Cayman).
- CollPlant Biotechnologies grew revenue faster in its latest fiscal year (+360.39% vs +9.20%).
About Cuprina (Cayman)
CUPR stock →Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name.
Health Care · Industrial Specialties · 10 employees
CUPR vs OPHI FAQ
Which is bigger, Cuprina (Cayman) or CollPlant Biotechnologies?
Cuprina (Cayman) (CUPR) is larger, with a market capitalization of $10.79M compared with $9.63M for CollPlant Biotechnologies (OPHI).
Are Cuprina (Cayman) and CollPlant Biotechnologies in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.